BLRX vs. CLNN, RAPT, CALC, CASI, LTRN, TPST, BRNS, PASG, ATNM, and ANEB
Should you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Clene (CLNN), RAPT Therapeutics (RAPT), CalciMedica (CALC), CASI Pharmaceuticals (CASI), Lantern Pharma (LTRN), Tempest Therapeutics (TPST), Barinthus Biotherapeutics (BRNS), Passage Bio (PASG), Actinium Pharmaceuticals (ATNM), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical products" industry.
BioLineRx vs.
Clene (NASDAQ:CLNN) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.
23.3% of Clene shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 25.1% of Clene shares are owned by company insiders. Comparatively, 1.1% of BioLineRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Clene has higher earnings, but lower revenue than BioLineRx. Clene is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
BioLineRx received 434 more outperform votes than Clene when rated by MarketBeat users. However, 79.12% of users gave Clene an outperform vote while only 71.98% of users gave BioLineRx an outperform vote.
Clene currently has a consensus price target of $55.25, suggesting a potential upside of 1,051.04%. BioLineRx has a consensus price target of $9.00, suggesting a potential upside of 8,471.43%. Given BioLineRx's higher possible upside, analysts clearly believe BioLineRx is more favorable than Clene.
BioLineRx has a net margin of -90.57% compared to Clene's net margin of -8,556.77%. BioLineRx's return on equity of -163.37% beat Clene's return on equity.
Clene has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.
In the previous week, BioLineRx had 9 more articles in the media than Clene. MarketBeat recorded 9 mentions for BioLineRx and 0 mentions for Clene. Clene's average media sentiment score of 0.00 beat BioLineRx's score of -0.08 indicating that Clene is being referred to more favorably in the media.
Summary
BioLineRx beats Clene on 10 of the 19 factors compared between the two stocks.
Get BioLineRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLineRx Competitors List
Related Companies and Tools
This page (NASDAQ:BLRX) was last updated on 1/21/2025 by MarketBeat.com Staff
